197 related articles for article (PubMed ID: 10720512)
41. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
42. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
White KL; Margot NA; Wrin T; Petropoulos CJ; Miller MD; Naeger LK
Antimicrob Agents Chemother; 2002 Nov; 46(11):3437-46. PubMed ID: 12384348
[TBL] [Abstract][Full Text] [Related]
43. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
Hanna GJ; Johnson VA; Kuritzkes DR; Richman DD; Brown AJ; Savara AV; Hazelwood JD; D'Aquila RT
J Infect Dis; 2000 Mar; 181(3):904-11. PubMed ID: 10720511
[TBL] [Abstract][Full Text] [Related]
44. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
45. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors.
Catucci M; Venturi G; Romano L; Riccio ML; De Milito A; Valensin PE; Zazzi M
J Acquir Immune Defic Syndr; 1999 Jul; 21(3):203-8. PubMed ID: 10421243
[TBL] [Abstract][Full Text] [Related]
46. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
Cozzi-Lepri A; De Luca A; Phillips AN; Bongiovanni M; Di Giambenedetto S; Mena M; Moioli MC; Arlotti M; Sighinolfi L; Narciso P; Lichtner M; Cauda R; Monforte Ad; ; ;
J Infect Dis; 2006 Jul; 194(1):20-8. PubMed ID: 16741878
[TBL] [Abstract][Full Text] [Related]
47. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.
Gu Z; Allard B; de Muys JM; Lippens J; Rando RF; Nguyen-Ba N; Ren C; McKenna P; Taylor DL; Bethell RC
Antimicrob Agents Chemother; 2006 Feb; 50(2):625-31. PubMed ID: 16436719
[TBL] [Abstract][Full Text] [Related]
48. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
[TBL] [Abstract][Full Text] [Related]
49. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo.
Walter H; Schmidt B; Werwein M; Schwingel E; Korn K
Antimicrob Agents Chemother; 2002 Jan; 46(1):89-94. PubMed ID: 11751116
[TBL] [Abstract][Full Text] [Related]
50. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.
Lanier ER; Sturge G; McClernon D; Brown S; Halman M; Sacktor N; McArthur J; Atkinson JH; Clifford D; Price RW; Simpson D; Torres G; Catalan J; Marder K; Power C; Hall C; Romero C; Brew B
AIDS; 2001 Apr; 15(6):747-51. PubMed ID: 11371689
[TBL] [Abstract][Full Text] [Related]
51. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.
McDowell JA; Lou Y; Symonds WS; Stein DS
Antimicrob Agents Chemother; 2000 Aug; 44(8):2061-7. PubMed ID: 10898676
[TBL] [Abstract][Full Text] [Related]
52. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication.
Bisset LR; Lutz H; Böni J; Hofmann-Lehmann R; Lüthy R; Schüpbach J
Antiviral Res; 2002 Jan; 53(1):35-45. PubMed ID: 11684314
[TBL] [Abstract][Full Text] [Related]
53. Abacavir.
Foster RH; Faulds D
Drugs; 1998 May; 55(5):729-36; discussion 737-8. PubMed ID: 9585869
[TBL] [Abstract][Full Text] [Related]
54. Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.
Underwood MR; Ross LL; Irlbeck DM; Gerondelis P; Rouse E; St Clair MH; Trinh L; Parkin N; Lanier E
J Infect Dis; 2009 Jan; 199(1):84-8. PubMed ID: 19032103
[TBL] [Abstract][Full Text] [Related]
55. Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
Holodniy M; Katzenstein D; Mole L; Winters M; Merigan T
J Infect Dis; 1996 Oct; 174(4):854-7. PubMed ID: 8843229
[TBL] [Abstract][Full Text] [Related]
56. Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.
Keiser P; Nassar N
Expert Opin Pharmacother; 2007 Mar; 8(4):477-83. PubMed ID: 17309342
[TBL] [Abstract][Full Text] [Related]
57. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.
Kline MW; Blanchard S; Fletcher CV; Shenep JL; McKinney RE; Brundage RC; Culnane M; Van Dyke RB; Dankner WM; Kovacs A; McDowell JA; Hetherington S
Pediatrics; 1999 Apr; 103(4):e47. PubMed ID: 10103339
[TBL] [Abstract][Full Text] [Related]
58. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.
Ray AS; Basavapathruni A; Anderson KS
J Biol Chem; 2002 Oct; 277(43):40479-90. PubMed ID: 12176989
[TBL] [Abstract][Full Text] [Related]
59. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
Tisdale M; Alnadaf T; Cousens D
Antimicrob Agents Chemother; 1997 May; 41(5):1094-8. PubMed ID: 9145875
[TBL] [Abstract][Full Text] [Related]
60. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.
van Praag RM; van Heeswijk RP; Jurriaans S; Lange JM; Hoetelmans RM; Prins JM
Clin Infect Dis; 2001 Oct; 33(8):e91-2. PubMed ID: 11565093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
